Peer-influenced content. Sources you trust. No registration required. This is HCN.
This question is answered in Blood Advances, which features a visual abstract on how ex vivo drug screening was performed within a clinically actionable time frame (median 15 days) and predicted clinical responses in vivo.
Hematology June 29th 2020
The FDA granted selinexor (Xpovio, Karyopharm Therapeutics), a nuclear transport inhibitor, accelerated approval for this indication based on the response rate seen in the SADAL trial, a phase 2, single-arm, open-label study of patients with DLBCL who had previously received two to five systemic regimens.
Healthgrades for Professionals
As a result of COVID-19, many physicians had to provide telemedicine services in a matter of weeks, if not days. A major accomplishment, for sure. But are you getting paid for your hard work? Read on to find out how you can ensure you are being compensated for the work you’ve been doing.
Allergy & Immunology June 22nd 2020
The 2020 Healthgrades National Health Index compared 100 markets based on a cross-section of factors that contribute to quality care and personal health. Here are the five cities that rise above the rest – did your city make the list?
Allergy & Immunology June 1st 2020
The New England Journal of Medicine
In this Journal of Clinical Oncology study, anetumab ravtansine yielded manageable safety, tolerability, pharmacokinetics, and clinical activity in a study of 148 heavily pretreated patients with mesothelin-expressing solid tumors.
Gastroenterology May 18th 2020
Hospitalized patients who had advanced COVID-19 with lung involvement and who received the antiviral agent remdesivir (Gilead Sciences) recovered faster than similar patients who received placebo, according to a preliminary data analysis from a US-led randomized, controlled trial.
Family Medicine/General Practice May 4th 2020